Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

eral cases of QTc prolongation were reported early in the study, but most resolved following a dose adjustment, and no Grade 4 cases have been reported in the subset of 62 patients.  One case of Grade 4 QTc prolongation has been observed in the entire study of 333 patients.  Management of other adverse events is also being explored with dose modifications in the ongoing study.

Detection of Phosphorylated and Total FLT3 and STAT5 in Whole Blood;

Modulation by Quizartinib (AC220) from Phase I and II Trials in AML

The pharmacodynamic effects of quizartinib treatment in AML patients was assessed using whole blood samples from patients enrolled in a previously performed Phase 1 study, and from the 62 patient subset in the Phase 2 study described above.  Proprietary and customized immunoassays were developed, optimized and validated at Ambit to detect both total (t) and phosphorylated (p) levels of FLT3, as well as the downstream signaling protein STAT5.  Blood samples were examined prior to treatment with quizartinib on Day 1 of treatment and again after either 8 or 15 days of treatment, depending upon study. 

Results from this assay demonstrated that following administration of quizartinib there was a profound, immediate and sustained pharmacodynamic effect in inhibiting both FLT3 and the subsequent downstream phosphorylation of the biologically important signaling protein, STAT5.  A mean pFLT3 inhibition of 80 percent was observed within 24-hours of the first dose, and there was a strong correlation with inhibiting phosphorylation of STAT5 (p < 0.007).  These findings support the linkage between FLT3 activation and downstream STAT5 activation, and demonstrate the ability of quizartinib to inhibit both of these important signaling molecules that are involved in the pathology of FLT3-ITD positive AML.  Results at later time points showed that approximately one half (47 per
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 During his ... understood the need to surround himself with great people ... and entrepreneur, his friends often marveled at his extraordinarily ... lived his life and -- even with his death ... the Alzheimer’s disease that would ultimately take his life. ...
(Date:11/22/2014)... Denver, Colo. (PRWEB) November 21, 2014 ... of proprietary cloud based analytics and scientific testing methodologies ... a commitment for a $750,000 line of credit from ... are extremely pleased to have secured this commitment from ... Chief Executive Officer of CannLabs. “This capital will help ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 On November ... at the 2014 Emerging Medical Technologies Summit in San ... Awards. Widely regarded among Silicon Valley investors and ... device innovation, the win also positions Briteseed to ... Innovator competition in 2015 and compete with other elite ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies,in the ... announced that on,August 6, 2008, the PRC,s ... China Biologic,s production facility in Taian City ...
... Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of vaccines ... scheduled for September 4, 2008 has been,adjourned to September ... General Meeting, the required quorum of,a majority of the ... the meeting is adjourned to September 18, 2008 (the ...
... PHILADELPHIA and LONDON, Sept. 4 Thomson ... for businesses and,professionals, announced today that the ... of scientists worldwide using BIOMARKERcenter, the,first comprehensive ... diagnostic, and research organizations with,a framework for ...
Cached Biology Technology:China Biologic's Production Facility Renews GMP Certification 2China Biologic's Production Facility Renews GMP Certification 3Sinovac Adjourns Annual General Meeting 2The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters 2The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters 3
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Ariz. and ROSEMONT, Ill. September 12, 2013 ... today announced that the Pac-12,s Arizona State University and ... first university research partner in a new study designed ... groundbreaking joint research project is the first of its ...
... softballs, both approved for league play, can have dramatically different ... findings from a study conducted by Professor Lloyd Smith in ... Derek Nevins that they will present at the Asia Pacific ... Their work was published in the journal, Procedia Engineering ...
... Sept. 12, 2013 Taking a page from ... Research Institute (TGen) today initiated the first-in-human clinical trial ... a plant known as "Thunder God vine." ... received treatment today at Scottsdale Healthcare,s Virginia G. Piper ...
Cached Biology News:ASU football program is first collegiate partner in TGen-Riddell concussion detection study 2ASU football program is first collegiate partner in TGen-Riddell concussion detection study 3ASU football program is first collegiate partner in TGen-Riddell concussion detection study 4Researchers hit virtual heads to make safer games 2TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 2TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 3
... Kits provide rapid and efficient removal of ... and salts from PCR products (Figure 1). ... two Binding Buffer options for fragments >100 ... performed in either single column or 96-well ...
...
Immunogen: Recombinant full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: